Physician
Mngi Digestive Health, P.A.
Mngi Digestive Health, P.A. was paid $21.58M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is J1745, Injection, infliximab, excludes biosimilar, 10 mg — 15% of everything it billed.
33Billing provider infoMNGI DIGESTIVE HEALTH, P.A.
MINNEAPOLIS, MN 55413
MINNEAPOLIS, MN 55413
33aNPI1609804541assigned 06/29/2006
33bProvider typeGastroenterology Physician
28Total paid$21.58M
24GClaims346,018
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Gastroenterology Physician providers in Minnesota
Rank by total paid#2 of 8
Median peer was paid$9K
This provider vs. median2,538×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,026 | $1.44M | |
| 2019 | 72,372 | $4.75M | |
| 2020 | 60,593 | $4.43M | |
| 2021 | 69,764 | $5.61M | |
| 2022 | 42,865 | $3.47M | |
| 2023 | 18,758 | $1.11M | |
| 2024incomplete | 12,640 | $777K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 15% | 1,929 | 1,280 | $3.19M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.9% | 28,961 | 27,471 | $1.70M |
| 00731 | 7.4% | 24,871 | 14,090 | $1.60M | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 7.3% | 26,410 | 25,395 | $1.58M |
| 00811 | 7.2% | 27,099 | 15,345 | $1.55M | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 6.1% | 880 | 596 | $1.32M |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 5.8% | 34,956 | 15,779 | $1.26M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.6% | 21,732 | 20,656 | $1.22M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.1% | 13,321 | 12,752 | $1.09M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 4.6% | 8,348 | 7,768 | $987K |
| 99254 | 3.6% | 7,613 | 7,165 | $781K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.3% | 9,056 | 8,609 | $708K |
66 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 3.3% | 18,533 | $703K |
| 99222 | Initial hospital care, per day, moderate complexity | 2.3% | 9,746 | $491K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.9% | 4,418 | $414K |
| 00813 | 1.9% | 4,803 | $414K | |
| 00812 | 1.7% | 5,264 | $359K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.5% | 3,462 | $327K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 1.1% | 53 | $241K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 2,900 | $217K |
| 99443 | <1% | 2,878 | $170K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 2,850 | $158K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,613 | $157K |
| 43235 | <1% | 2,713 | $144K | |
| 99442 | <1% | 3,189 | $126K | |
| 88342 | <1% | 1,344 | $78K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,809 | $77K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 690 | $63K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,319 | $46K |
| 80053 | Comprehensive metabolic panel | <1% | 5,201 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,952 | $41K |
| 80076 | <1% | 6,249 | $37K | |
| 82784 | <1% | 4,484 | $34K | |
| 97802 | <1% | 602 | $34K | |
| 91065 | <1% | 532 | $21K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,004 | $20K |
| 82105 | <1% | 1,364 | $17K | |
| 99441 | <1% | 546 | $15K | |
| 86140 | <1% | 3,448 | $13K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 487 | $12K |
| 99243 | <1% | 255 | $12K | |
| 85027 | <1% | 1,905 | $9K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 167 | $9K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 124 | $7K |
| 43264 | <1% | 38 | $7K | |
| 87340 | <1% | 866 | $7K | |
| 83690 | <1% | 1,345 | $7K | |
| 87507 | <1% | 14 | $7K | |
| 82728 | <1% | 597 | $7K | |
| 97803 | <1% | 260 | $6K | |
| 83550 | <1% | 788 | $5K | |
| 83540 | <1% | 828 | $4K | |
| 85610 | <1% | 1,216 | $4K | |
| 86706 | <1% | 442 | $3K | |
| 83014 | <1% | 436 | $3K | |
| 96415 | <1% | 574 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 55 | $2K |
| 43248 | <1% | 24 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 185 | $2K |
| 85652 | <1% | 950 | $2K | |
| 86704 | <1% | 134 | $1K | |
| 82248 | <1% | 349 | $1K | |
| 43762 | <1% | 12 | $1K | |
| 99253 | <1% | 14 | $1K | |
| 76981 | <1% | 13 | $1K | |
| 43262 | <1% | 12 | $974.00 | |
| 86803 | <1% | 76 | $969.72 | |
| 86708 | <1% | 66 | $825.35 | |
| 82565 | <1% | 212 | $778.12 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 66 | $713.98 |
| 82607 | <1% | 44 | $657.64 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 166 | $650.53 |
| 45330 | <1% | 13 | $383.38 | |
| 90674 | <1% | 12 | $196.16 | |
| 98968 | <1% | 19 | $72.50 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 0% | 69 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 12 | $0.00 |
| 91200 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKETOVER, SCOTT (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mngi Endoscopy Asc INC | Minneapolis, MN | $5.62M |
| Affiliated Endoscopy Centers, LLC | Vadnais Heights, MN | $2.02M |
| Community Anesthesia Professionals PLLC | St Paul, MN | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.